Molina Healthcare (NYSE: MOH) details Q4 2025 results and 2026 guidance

Rhea-AI Filing Summary

Molina Healthcare, Inc. filed a current report stating that it issued a press release with its financial results for the fourth quarter and year ended December 31, 2025, as well as full-year 2026 revenue and earnings guidance.

The press release is provided as Exhibit 99.1 to the report, and any information on the company’s website referenced in that release is expressly excluded from being part of this report.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001179929false00011799292026-02-052026-02-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________

FORM 8-K

______________

Current Report

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 5, 2026

______________

MOLINA HEALTHCARE, INC.

(Exact name of registrant as specified in its charter)

Delaware			1-31719			13-4204626
(State or other jurisdiction of incorporation)			(Commission File Number)			(IRS Employer Identification No.)

______________

200 Oceangate, Suite 100,			Long Beach,			California			90802
(Address of principal executive offices)									(Zip Code)

Registrant’s telephone number, including area code: (562) 435-3666

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, $0.001 Par Value			MOH			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act.

☐

Item 2.02.    Results of Operations and Financial Condition.

On February 5, 2026, Molina Healthcare, Inc. (the “Company”) issued a press release reporting its financial results for the fourth quarter and year ended December 31, 2025 and the Company’s full-year 2026 revenue and earnings guidance. The full text of the press release is included as Exhibit 99.1 to this report. The information contained in the Company’s website cited in the press release is not part of this report.

Note: The information in this Form 8-K and the exhibits attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01.    Financial Statements and Exhibits.

(d)     Exhibits:

Exhibit No.			Description
99.1			Press release of Molina Healthcare, Inc., issued February 5, 2026.
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						MOLINA HEALTHCARE, INC.
Date:			February 5, 2026			By:			/s/ Jeff D. Barlow
									Jeff D. Barlow
									Chief Legal Officer and Secretary

FAQ

What did Molina Healthcare (MOH) disclose in this 8-K filing?

Molina Healthcare disclosed that it issued a press release reporting its fourth-quarter and full-year 2025 financial results, along with full-year 2026 revenue and earnings guidance. The complete press release is attached as Exhibit 99.1 to the current report.

Which period’s results are covered by Molina Healthcare’s latest press release?

The press release covers Molina Healthcare’s financial results for the fourth quarter and the full year ended December 31, 2025. It also includes the company’s revenue and earnings guidance for the full year 2026, giving investors visibility into the next year’s expectations.

Where can investors find the detailed Q4 and 2025 results for Molina Healthcare (MOH)?

Detailed Q4 and full-year 2025 results for Molina Healthcare are contained in the press release attached as Exhibit 99.1 to the 8-K. The filing clarifies that information on the company’s website referenced in the release is not considered part of the report.

Does the Molina Healthcare 8-K include 2026 guidance information?

Yes. The 8-K states that Molina Healthcare’s press release provides the company’s full-year 2026 revenue and earnings guidance. This guidance, along with historical 2025 results, is contained within Exhibit 99.1 rather than directly in the body of the current report.

Who signed the Molina Healthcare (MOH) 8-K reporting Q4 2025 results?

The 8-K was signed on behalf of Molina Healthcare, Inc. by Jeff D. Barlow, the company’s Chief Legal Officer and Secretary, dated February 5, 2026. His signature confirms the company’s authorization of the disclosure contained in the current report.